Phosphodiesterase type 5 inhibitors for premature ejaculation: advances in studies.
- Author:
Dun-sheng MO
;
Xue-jun SHANG
;
Yu-feng HUANG
- Publication Type:Journal Article
- MeSH:
Ejaculation;
drug effects;
Erectile Dysfunction;
drug therapy;
Humans;
Male;
Muscle Contraction;
Phosphodiesterase 5 Inhibitors;
therapeutic use;
Premature Ejaculation;
drug therapy;
Seminal Vesicles;
physiology;
Vas Deferens;
physiology
- From:
National Journal of Andrology
2015;21(6):561-565
- CountryChina
- Language:Chinese
-
Abstract:
Premature ejaculation (PE) is a common male sexual disorder with an incidence rate of 20-30%. Recent clinical trials have demonstrated that phosphodiesterase type 5 inhibitors (PDE5i), as the first-line drug for erectile dysfunction (ED), can improve ejaculatory function probably by acting on the peripheral and central adrenergic nerves. The possible action mechanisms of PDE5i may involve lessening of the central sympathetic output, modulation of the contractile responses from the vas deferens, seminal vesicles, prostate and urethra, induction of peripheral analgesia, and prolonging of the total erectile duration, increasing the confidence of ejaculation control, and reducing the post-ejaculation refractory time. This review discusses the possible mechanisms and clinical application of PDE5i in the treatment of PE.
